Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study

References

• Gillman MA, Lichtigfeld FJ. A pharmacological overview of opioid mechanisms mediating analgesia and hyperalgesia. Neurological Res. 1985;7(3):106–119. doi:10.1080/01616412.1985.11739709
   PubMedGoogle Scholar
• Swidan S, Bennett M. Advanced Therapeutics in Pain Medicine. Milton: CRC Press; 2020.
   Google Scholar
• Poliwoda S, Noss B, Truong GTD, et al. The Utilization of Low Dose Naltrexone for Chronic Pain. CNS Drugs. 2023;37(8):663–670. doi:10.1007/s40263-023-01018-3
   PubMed Web of Science ®Google Scholar
• Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor–G protein coupling and Gβγ signaling. Neuroscience. 2005;135(1):247–261. doi:10.1016/j.neuroscience.2005.06.003
   PubMed Web of Science ®Google Scholar
• Kurta AO, Weinstock LB, Semchyshyn N. Erythromelalgia in a Patient with Mast Cell Activation Syndrome: response to Low Dose Naltrexone. SKIN J Cutaneous Med. 2020;4(3):288. doi:10.25251/skin.4.3.15
   Google Scholar
• Zhang X, Wang Y, Dong H, Xu Y, Zhang S. Induction of Microglial Activation by Mediators Released from Mast Cells. Cell. Physiol. Biochem. 2016;38(4):1520–1531. doi:10.1159/000443093
   PubMedGoogle Scholar
• Burns LH, Wang H-Y. Ultra-Low-Dose Naloxone or Naltrexone to Improve Opioid Analgesia: the History, the Mystery and a Novel Approach. Clin Med Insight. 2010;2010(2):CMT.S4870. doi:10.4137/CMT.S4870
   Google Scholar
• Dara P, Farooqui Z, Mwale F, Choe C, van Wijnen AJ, Im HJ. Opiate Antagonists for Chronic Pain: a Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases. Biomedicines. 2023;11(6):1620.
   PubMed Web of Science ®Google Scholar
• Bruun-Plesner K, Blichfeldt-Eckhadt MR, Vaegter HB, Lauridsen JT, Amris K, Toft P. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. Pain Med. 2020;21(10):2253–2261.
   PubMed Web of Science ®Google Scholar
• Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.(Report)(Author abstract). Clin Rheumatol. 2014;33(4):451. doi:10.1007/s10067-014-2517-2
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Peng Y, et al. Pharmacological characterization of the opioid inactive isomers (+)‐naltrexone and (+)‐naloxone as antagonists of toll‐like receptor 4. Br. J. Pharmacol. 2016;173(5):856–869. doi:10.1111/bph.13394
   PubMed Web of Science ®Google Scholar
• Shen KF, Crain SM. Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res. 1989;491(2):227–242. doi:10.1016/0006-8993(89)90059-0
   PubMed Web of Science ®Google Scholar
• Crain SM, Shen K-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci. 1990;11(2):77–81. doi:10.1016/0165-6147(90)90322-Y
   PubMed Web of Science ®Google Scholar
• Kendig EL, Le HH, Belcher SM. Defining Hormesis: evaluation of a Complex Concentration Response Phenomenon. Int J Toxicol. 2010;29(3):235–246. doi:10.1177/1091581810363012
   PubMed Web of Science ®Google Scholar
• Katsnelson BA, Panov VG, Minigalieva IA, et al. On an extended understanding of the term “hormesis” for denoting alternating directions of the organism’s response to increasing adverse exposures. Toxicology. 2021;447:152629.
   PubMed Web of Science ®Google Scholar
• Stossel TP, Condeelis J, Cooley L, et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol. 2001;2:138–145.
   PubMed Web of Science ®Google Scholar
• Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Adding Ultralow-Dose Naltrexone to Oxycodone Enhances and Prolongs Analgesia:A Randomized, Controlled Trial of Oxytrex. J Pain. 2005;6:392–399.
   PubMed Web of Science ®Google Scholar
• Haight ES, Forman TE, Cordonnier SA, James ML, Tawfik VL. Microglial Modulation as a Target for Chronic Pain: from the Bench to the Bedside and Back. Anesthesia Analg. 2019;128(4):737–746. doi:10.1213/ANE.0000000000004033
   PubMed Web of Science ®Google Scholar
• Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Medical Sci. 2018;6(4):82. doi:10.3390/medsci6040082
   Google Scholar
• Kučić N, Rački V, Šverko R, Vidović T, Grahovac I, Mršić‐pelčić J. Immunometabolic modulatory role of naltrexone in bv‐2 microglia cells. Int J Mol Sci. 2021;22(16):8429. doi:10.3390/ijms22168429
   PubMed Web of Science ®Google Scholar
• Liu B, Du L, Hong JS. Naloxone Protects Rat Dopaminergic Neurons against Inflammatory Damage through Inhibition of Microglia Activation and Superoxide Generation. J Pharmacol Exp Ther. 2000;293:607–617.
   PubMed Web of Science ®Google Scholar
• Xu N, Wang Y, Zhao S, et al. Naltrexone (NTX) relieves inflammation in the collagen-induced-arthritis (CIA) rat models through regulating TLR4/NfĸB signaling pathrway. Int Immunopharmacol. 2020;79:106056.
   PubMed Web of Science ®Google Scholar
• Conti P, Lauritano D, Caraffa A, et al. Microglia and mast cells generate proinflammatory cytokines in the brain and worsen inflammatory state: suppressor effect of IL-37. Eur. J. Pharmacol. 2020;875:173035.
   PubMed Web of Science ®Google Scholar
• Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol. 2014;14:217–231.
   PubMed Web of Science ®Google Scholar
• Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int Immunopharmacol. 2018;61:178–184. doi:10.1016/j.intimp.2018.05.020
   PubMed Web of Science ®Google Scholar
• McLaughlin PJ, Sassani JW, Diaz D, Zagon IS. Elevated Opioid Growth Factor Alters the Limbus in Type I Diabetic Rats. J Diabetes Clin Res. 2023;5(1):1–10.
   PubMedGoogle Scholar
• Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2008;72(3):333–337. doi:10.1016/j.mehy.2008.06.048
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163–172. doi:10.1056/NEJMra1409760
   PubMed Web of Science ®Google Scholar
• Valent P, Hartmann K, Bonadonna P, et al. Global Classification of Mast Cell Activation Disorders: an ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium. j Allergy Clin Immunol Practice. 2022;10(8):1941–1950. doi:10.1016/j.jaip.2022.05.007
   PubMed Web of Science ®Google Scholar
• Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers–Danlos syndrome. Am J Med Genet Part C. 2017;175(1):226–236. doi:10.1002/ajmg.c.31555
   PubMed Web of Science ®Google Scholar
• Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology. 2014;141(3):314–327. doi:10.1111/imm.12170
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Perman AII, Twahir A, Kempuraj, D. Mast cell activation: beyond histamine and tryptase. Expert Rev Clin Immunol. 2023;19(6):639–654. doi:10.1080/1744666X.2023.2200936.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Twahir A, Kempuraj D. Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation. Ann Allergy Asthma Immunol. 2023:S1081-1206(23):01397–2. doi:10.1016/j.anai.2023.10.032
   Google Scholar
• Marcus N, Gracely E, Keefe K. A comprehensive protocol to diagnose and treat pain of muscular origin may successfully and reliably decrease or eliminate pain in a chronic pain population. Pain Med. 2010;11(1):25–34.
   PubMed Web of Science ®Google Scholar
• Marcus N, Mense S. Muscle Pain: pathophysiology, Evaluation and Treatment. In: Warfield C, Bajwa Z, Wootton J, editors. Principles and Practice of Pain Medicine. 3rd. McGraw-Hill; 2012.
   Google Scholar
• Kosek E, Clauw D, Nijs J, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain. 2021;162(11):2629–2634. doi:10.1097/j.pain.0000000000002324
   PubMed Web of Science ®Google Scholar
• IASP (2024, January 29). Terminology. Available from: https://www.iasp-pain.org/resources/terminology/#:~:text=NOCICEPTIVE%20PAIN*,to%20contrast%20with%20neuropathic%20pain. Accessed March 8, 2024.
   Google Scholar
• Mense S, Gerwin RD. Functional Anatomy of Muscle: Muscle, Nociceptors and Afferent Fibers. Germany: Springer Berlin / Heidelberg; 2010:17–48.
   Google Scholar
• Simons DG. Diagnostic Criteria of Myofascial Pain Caused by Trigger Points. J Musculoskelet Pain. 1999;7(1–2):111–120. doi:10.1300/J094v07n01_11
   Web of Science ®Google Scholar
• Gensemer C, Burks R, Kautz S, Judge DP, Lavallee M, Norris RA. Hypermobile Ehlers‐Danlos syndromes: complex phenotypes, challenging diagnoses, and poorly understood causes. Dev. Dyn. 2021;250(3):318–344. doi:10.1002/dvdy.220
   PubMed Web of Science ®Google Scholar
• Marcus N, Brock I. Low-dose Naltrexone (LDN): dose Determination for Nociplastic Pain in HSD/hEDS. presented at: 2022 EDS International Scientific Symposium; 2022; Rome, Italy.
   Google Scholar
• Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet Part C. 2017;175(1):48–69. doi:10.1002/ajmg.c.31538
   PubMed Web of Science ®Google Scholar
• Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers–Danlos syndromes. Am J Med Genet Part C. 2017;175(1):212–219. doi:10.1002/ajmg.c.31554
   PubMed Web of Science ®Google Scholar
• Frech T, Novak K, Revelo MP, et al. Low-Dose Naltrexone for Pruritus in Systemic Sclerosis. Int j Rheumatol. 2011;2011:804296. doi:10.1155/2011/804296
   PubMedGoogle Scholar
• Stancil SL, Nolte W, Pearce RE, Staggs VS, Leeder JS. The Impact of Age and Genetics on Naltrexone Biotransformation. Drug Metab. Dispos. 2022;50(2):168–173. doi:10.1124/DMD.121.000646
   PubMed Web of Science ®Google Scholar
• Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low‐Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn’s Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086
   PubMed Web of Science ®Google Scholar
• Marcus N. The Role of Muscle Dysfunction in Pain and Mobility in EDS. In: Daens S, editor. Transforming Ehlers-Danlos Syndrome. The GERSED; 2022:520–553.
   Google Scholar
• McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: a Case Series. J Pain Res. 2023;1993–1998.
   PubMed Web of Science ®Google Scholar